• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    3/18/24 1:31:33 PM ET
    $AHG
    $BTCY
    $CDXC
    $CMAX
    Real Estate
    Real Estate
    Medical/Dental Instruments
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Fresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million.
    • Akso Health Group (NASDAQ:AHG) stock moved upwards by 29.0% to $1.29. The company's market cap stands at $141.3 million.
    • ChromaDex (NASDAQ:CDXC) stock moved upwards by 27.91% to $3.07. The company's market cap stands at $231.1 million.
    • Elicio Therapeutics (NASDAQ:ELTX) stock moved upwards by 24.0% to $6.2. The market value of their outstanding shares is at $59.5 million.
    • Immuneering (NASDAQ:IMRX) stock increased by 23.04% to $2.35. The company's market cap stands at $68.8 million.
    • Biotricity (NASDAQ:BTCY) stock rose 21.08% to $1.55. The company's market cap stands at $14.5 million.

    Losers

    • Trxade Health (NASDAQ:MEDS) shares declined by 33.0% to $19.3 during Monday's regular session. The market value of their outstanding shares is at $23.2 million.
    • Envoy Medical (NASDAQ:COCH) shares declined by 27.6% to $3.62. The market value of their outstanding shares is at $70.7 million.
    • CareMax (NASDAQ:CMAX) shares decreased by 25.28% to $4.14. The market value of their outstanding shares is at $15.5 million. The company's, Q4 earnings came out today.
    • Titan Pharma (NASDAQ:TTNP) shares fell 18.34% to $7.59. The market value of their outstanding shares is at $5.7 million.
    • Cargo Therapeutics (NASDAQ:CRGX) stock declined by 17.67% to $25.75. The company's market cap stands at $1.0 billion.
    • Molecular Templates (NASDAQ:MTEM) shares fell 17.28% to $2.27. The market value of their outstanding shares is at $12.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $BTCY
    $CDXC
    $CMAX

    CompanyDatePrice TargetRatingAnalyst
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025Buy → Neutral
    Chardan Capital Markets
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025$32.00 → $3.00Buy → Hold
    Jefferies
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025$34.00 → $4.00Overweight → Neutral
    Piper Sandler
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025Outperform → Mkt Perform
    William Blair
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025Overweight → Underweight
    Analyst
    CARGO Therapeutics Inc.
    $CRGX
    1/30/2025$32.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Inhibitors of RAS, RAF, or MEK often provide only temporary benefit due to resistance, as tumors acquire new mutations or mechanisms of escape within the MAPK pathway. Atebimetinib, a novel Deep Cyclic

    3/17/26 4:35:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on March 16, 2026, Elicio granted an aggregate of 1,600 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. The grant provides for the

    3/17/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Event-driven primary disease-free survival ("DFS") analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC") is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026 BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of n

    3/12/26 4:05:00 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $AHG
    $BTCY
    $CDXC
    $CMAX
    SEC Filings

    View All

    SEC Form EFFECT filed by Elicio Therapeutics Inc.

    EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/17/26 12:15:11 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:19:42 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Elicio Therapeutics Inc.

    424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:18:38 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Elicio Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $17.00

    3/10/26 8:40:26 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CARGO Therapeutics downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded CARGO Therapeutics from Buy to Neutral

    1/30/25 7:52:27 AM ET
    $CRGX

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 5:27:12 PM ET
    $AHG
    Real Estate

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 10:16:26 AM ET
    $AHG
    Real Estate

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 10:00:57 AM ET
    $AHG
    Real Estate

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Leadership Updates

    Live Leadership Updates

    View All

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BTCY
    $CDXC
    $CMAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CARGO Therapeutics Inc.

    SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)

    11/14/24 5:45:26 PM ET
    $CRGX